VivoSeq
Other

Brain Edema

8

Pipeline Programs

0

Active Trials

4

Companies Involved

Brain Edema is an early-stage landscape with 8 programs across 4 companies. The most active players are Milestone Pharmaceuticals Inc., Novo Nordisk, Celtic Pharma Development Services. 3 therapies are approved with 1 more in late-stage development.

Pipeline Metrics

Competitive Density

33/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

50/100

Attrition Rate

40/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Modality Breakdown

91%

Small molecule

10 of 11 classified programs — the dominant modality here.

9%ALL OTHERSProtein / enzyme19%

Small molecule leads; the ring shows all 11 classified programs, each share of the total. Modality classified for 100% of 11 pipeline programs.

Trial Status

5

clinical trials

Completed2 · 40%
Terminated1 · 20%
Withdrawn1 · 20%
Unknown status1 · 20%

Trial Activity

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)